74,877 Shares in BioLife Solutions, Inc. (NASDAQ:BLFS) Bought by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC acquired a new stake in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 74,877 shares of the medical equipment provider's stock, valued at approximately $1,605,000. Lisanti Capital Growth LLC owned approximately 0.16% of BioLife Solutions at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Conestoga Capital Advisors LLC lifted its position in BioLife Solutions by 1.0% during the first quarter. Conestoga Capital Advisors LLC now owns 65,477 shares of the medical equipment provider's stock valued at $1,215,000 after buying an additional 630 shares in the last quarter. Louisiana State Employees Retirement System increased its holdings in BioLife Solutions by 4.0% in the 2nd quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider's stock valued at $392,000 after purchasing an additional 700 shares in the last quarter. Sei Investments Co. raised its position in BioLife Solutions by 1.4% in the first quarter. Sei Investments Co. now owns 60,191 shares of the medical equipment provider's stock valued at $1,117,000 after purchasing an additional 839 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of BioLife Solutions by 10.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,129 shares of the medical equipment provider's stock worth $281,000 after purchasing an additional 1,374 shares in the last quarter. Finally, Texas Permanent School Fund Corp boosted its position in shares of BioLife Solutions by 4.7% in the first quarter. Texas Permanent School Fund Corp now owns 31,145 shares of the medical equipment provider's stock worth $578,000 after buying an additional 1,384 shares during the period. Hedge funds and other institutional investors own 93.24% of the company's stock.

Insiders Place Their Bets

In other BioLife Solutions news, insider Sarah Aebersold sold 3,000 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $21.03, for a total transaction of $63,090.00. Following the sale, the insider now directly owns 61,683 shares of the company's stock, valued at $1,297,193.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other BioLife Solutions news, CMO Todd Berard sold 10,000 shares of the firm's stock in a transaction on Friday, June 14th. The stock was sold at an average price of $20.18, for a total value of $201,800.00. Following the sale, the chief marketing officer now directly owns 108,894 shares in the company, valued at $2,197,480.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Sarah Aebersold sold 3,000 shares of the company's stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $21.03, for a total transaction of $63,090.00. Following the transaction, the insider now owns 61,683 shares of the company's stock, valued at approximately $1,297,193.49. The disclosure for this sale can be found here. 2.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have issued reports on BLFS shares. StockNews.com raised shares of BioLife Solutions to a "sell" rating in a research report on Friday, May 10th. TD Cowen boosted their price objective on shares of BioLife Solutions from $20.00 to $26.00 and gave the stock a "buy" rating in a report on Wednesday, July 17th. Benchmark upgraded BioLife Solutions from a "neutral" rating to a "buy" rating and set a $25.00 target price for the company in a research note on Monday, May 13th. Craig Hallum boosted their price target on BioLife Solutions from $23.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday, August 12th. Finally, Northland Securities raised their price objective on BioLife Solutions from $26.00 to $28.00 and gave the company an "outperform" rating in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $26.20.

BioLife Solutions Stock Down 0.2 %

Shares of BioLife Solutions stock traded down $0.04 during trading on Friday, reaching $25.88. The company had a trading volume of 394,425 shares, compared to its average volume of 382,129. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.81 and a current ratio of 2.86. BioLife Solutions, Inc. has a fifty-two week low of $8.92 and a fifty-two week high of $26.73. The firm's fifty day moving average is $22.99 and its 200-day moving average is $20.23. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -18.23 and a beta of 1.85.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.08. BioLife Solutions had a negative return on equity of 10.75% and a negative net margin of 59.88%. The firm had revenue of $28.33 million for the quarter, compared to analysts' expectations of $23.80 million. On average, analysts anticipate that BioLife Solutions, Inc. will post -0.37 EPS for the current year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.